Pharma Dynamics

Jump to

Expect FY16 US generic launch for Nexium: Lupin

In an interview with CNBC-TV18, CFO S Ramesh spoke to Latha Venkatesh and Sonia Shenoy about a recent acquisition and other developments such as a recent FDA audit at its Indore facility as well as its plans to launch a generic version of the world‘s second-largest-selling drug Nexium in the US.
Lupin Q3 net at record high, co buys Netherlands' Nanomi

Net profit increased to a record level of Rs 476.1 crore as against Rs 335.2 crore in same quarter last year while revenue grew 20.8 percent year-on-year to Rs 3,022 crore in the quarter gone by.
No plans to sell India biz, to be $3bn co by FY14: Lupin

Drug maker Lupin today assured shareholders that it has no plans to sell its India business and said the company aims to be a USD 3-billion firm by FY14.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Pharma Dynamics

Expect FY16 US generic launch for Nexium: Lupin

Lupin Q3 net at record high, co buys Netherlands' Nanomi

No plans to sell India biz, to be &#36;3bn co by FY14: Lupin

No plans to sell India biz, to be $3bn co by FY14: Lupin